Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial - Wherrett, Diane K; Bundy, Brian; Becker, Dorothy J; DiMeglio, Linda A; Gitelman, Stephen E; Goland, Robin; Gottlieb, Peter A; Greenbaum, Carla J; Herold, Kevan C; Marks, Jennifer B; Monzavi, Roshanak; Moran, Antoinette; et al. (The Lancet (British edition), 2011)
Keywords: Adolescent; Alum; Aluminum; Aluminum hydroxide; Animal models; antigens; Antigens - immunology; Antigens - therapeutic use; Autoimmune Diseases - immunology; Autoimmune Diseases - therapy; autoimmunity; Biological and medical sciences; blood serum; c-peptide; Canada; Child; Child, Preschool; Clinical trials; Data collection; Diabetes; Diabetes Mellitus, Type 1 - immunology; Diabetes Mellitus, Type 1 - therapy; Diabetes. Impaired glucose tolerance; Double-Blind Method; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; General aspects; Glutamate Decarboxylase - immunology; Glutamate Decarboxylase - therapeutic use; glutamic acid; hemoglobin; human resources; Humans; Immunization; Immunotherapy; Immunotherapy, Active; insulin secretion; insulin-dependent diabetes mellitus; Internal Medicine; Lines of credit; Male; Medical sciences; Middle Aged; National Institutes of Health; patients; Pharmaceuticals; United States; vaccines; Young Adult; Canada; United States; Endocrinopathy; Human; Immunopathology; Enzyme; Vaccination; Patient; Autoimmune disease; Lyases; Glutamate decarboxylase; Vaccine; Antigen; Medicine; Carbon-carbon lyases; Randomization; Treatment; Age of onset; Type 1 diabetes; Carboxy-lyases; Double blind study; Clinical trial